Amgen

Open: 224.75 Close: 222.61 Change: -2.14

11 lessons that an AI found about Amgen Company Inc after reading internet.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

FTC sues to block Amgen $27.8 billion deal to buy Horizon Therapeutics PLC (HZNP.O) Amgen struck a deal last year to. buy Horizon to strengthen its rare diseases drugs portfolio.

Today's News

FTC seeks to block Amgens Horizon buy in alarming sign for M&A. Amgen and Horizon said that they would not abandon the deal and would go to court. Amgen and Horizon Therapeutics said they believe they will be able to complete the deal by mid-December after responding to the lawsuit in court. Amgen said it was disappointed by the FTCs complaint, and that the merger poses no competitive issues. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgens $27.8 billion deal to buy Horizon Therapeutics PLC (HZNP.O) Amgen struck a deal last year to. buy Horizon to strengthen its rare diseases drugs portfolio. Federal Trade Commission sues to block biopharmaceutical giant Amgen from acquisition that would entrench monopoly drugs used to treat thyroid eye disease and chronic refractory gout treatments. FTC filed a lawsuit in federal court to block the transaction. Federal Trade Commission sues to block Amgen $26B deal for Horizon Therapeutics. Regulators said the deal would give Amgen unfair leverage to block competition. Amgen drops drug delivery partnership, Targets Crohns Disease with TScan Pact. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. FTC sues to stop Amgen $27.8B deal for Horizon Therapeutics. Amgen (amgn) stock price, quote, news & analysis - tipranks.com.com. Amgen announced plans to buy Horizon in December, saying that its rare disease drugs would offer it some protection from the drug pricing provisions. Federal regulators are suing to block biotech drug developer Amgens more than $26 billion deal for Horizon Therapeutics. FTC said the deal would give Amgen unfair leverage to block competition for Horizon medications. FTC sues to block Amgen $27.8 billion deal to acquire Horizon Therapeutics. FTC is attempting to stop the sale out of fears it will give the company too much power over rare disease treatments. Federal Trade Commission sues to block Amgens $27.8 billion purchase of Horizon Therapeutics. FTC Suing To Stop Amgens $27.8 Billion Purchase Of Horizon. Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commissions (FTC) complaint seeking to block the proposed acquisition of Horizon Therapeutics. Federal Trade Commission (FTC) announced Tuesday that it will oppose the Amgen-Horizon deal on grounds it will stifle innovation. Federal Trade Commission said it is seeking to block Amgen s $27.8 billion acquisition of Horizon Therapeutics. FTC said Tuesday that the deal would give Amgen unfair leverage to block competition for Horizon medications. Amgen to cut about 450 jobs in second round of layoffs this year Mar. ET by Barrons Amgen Raises 2023 Revenue, EPS Outlook Apr. ET Amgen 1Q Net Income Surges Despite 2% Dip in Revenue. Amgen has said previously that it expects the deal to close by the end of the year, and CEO Robert Bradway has said that hes “confident” the deal will complete.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, deal, block, FTC, say, Therapeutics, and the most common words in the summary are: amgen, stock, horizon, news, ftc, amgens, deal, . One of the sentences in the summary was: FTC sues to block Amgen $27.8 billion deal to buy Horizon Therapeutics PLC (HZNP.O) Amgen struck a deal last year to. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #horizon #news #ftc #amgens #deal.